bullish
Clinuvel Pharmaceuticals (CUV AU): 38% Revenue Growth Led to Sixth Consecutive Profitable Year
161 Views31 Aug 2022 18:26
SUMMARY
- Clinuvel Pharmaceuticals (CUV AU) announced strong FY22 performance, with 38% y/y revenue growth to A$67 million. Profit before tax increased 33% y/y to A$34.3 million.
- The cash reserves increased 47% y/y to A$121.51 million as of June 30, 2022. Balance sheet is strong with no debt, and high liquidity due to the accumulated cash reserves.
- Increasing penetration of Scenesse in existing jurisdictions and new jurisdictions, and extend the use of afamelanotide to adolescent EPP patients should drive near-term growth of the company.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Clinuvel Pharmaceuticals (CUV AU): Portfolio Expansion Ensures Continued Profitable Growth06 May 2023
- Clinuvel Pharmaceuticals (CUV AU): Strong Start of FY23; Pipeline Progress Enhances Conviction31 Dec 2022
- Clinuvel Pharmaceuticals (CUV AU): 38% Revenue Growth Led to Sixth Consecutive Profitable Year31 Aug 2022
- Clinuvel Pharmaceuticals (CUV AU): Great Marketed Product; Strong Financials; Rich Pipeline02 Aug 2022
- Clinuvel Pharmaceuticals (CUV AU): A Profitable Growth Story, With Sustainable Long-Term Future29 Apr 2022
x